Hexamethylenetetramines Group

These substances were identified for action under the Chemicals Management Plan (CMP). The screening assessment focuses on 3 substances referred to collectively as the Hexamethylenetetramines Group.

Information sheet

Hexamethylenetetramines Group

Summary of publications
Timelines

**Summary of publications**
Substance group	CAS RN	Common name	DSL name	Draft screening assessment	Risk management scope	Proposed conclusion on section 64 criteria	Follow-up activities
Hexamethylenetetramines Group	4080-31-3^{Footnote a}	Quaternium-15^{Footnote b} Cis/trans-CTAC	3,5,7-Triaza-1-azoniatricyclo[3.3.1.1³,7]decane, 1-(3-chloro-2-propenyl)-, chloride	HTML	HTML	Meets one or more of the criteria	Refer to risk management scope
	51229-78-8^{Footnote c}	Quaternium-15^{Footnote d} Cis-CTAC	3,5,7-Triaza-1-azoniatricyclo[3.3.1.1³,7]decane, 1-(3-chloro-2-propenyl)-, chloride, (Z)-		HTML	Meets one or more of the criteria	Refer to risk management scope
	58713-21-6^{Footnote c}	Methenamine hydrochloride	1,3,5,7-Tetraazatricyclo[3.3.1.1³,7]decane, hydrochloride		None	Does not meet	None planned at this time
Footnote 1 This CAS RN is a mixture of cis- and trans-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride (CTAC). Return to footnote a referrer Footnote 2 According to the European Commission database for information on cosmetic substances and ingredients (CosIng), "Quaternium-15" is represented by CAS RN 4080-31-3 or by a mixture containing CAS RN 4080-31-3 and CAS RN 51229-78-8. Return to footnote b referrer Footnote 3 This substance was not identified under subsection 73(1) of the Canadian Environmental Protection Act, 1999 but was included in this assessment as it was considered a priority on the basis of other human health concerns. Return to footnote c referrer Footnote 4 The Scientific Committee on Consumer Safety in Europe (SCCS) uses the term "Quaternium-15" to refer to cis-CTAC (CAS RN 51229-78-8). Return to footnote d referrer

**Timelines**
Date	Activity
March 2022	Anticipated publication of the final screening assessment and proposed risk management approach.
March 6, 2021	Publication and start of 60-day public comment period on the Draft Screening Assessment for the Hexamethylenetetramines Group and the Risk Management Scope for Certain Substances in the Hexamethylenetetramines Group. The related notice was published in the Canada Gazette, Part I: Vol. 155, No. 10.

Page details

Date modified:: 2021-03-05